BenchSci

🚀 Toronto’s AI and healthcare communities are coming together again — and we’re proud to share that our very own Yusuf Bismilla, VP of Product at BenchSci, will be speaking at the next TAPNET event! Yusuf will join a panel of trailblazers advancing AI beyond research into real-world impact. He’ll be joined by: 🌟 James Hong, Ph.D., Founder & CEO of Verismo Health & Verismo AI 🌟 Sanjana Basu, Partner at Radical Ventures 🌟 Denys Linkov, Head of ML at Wisedocs and UofT Lecturer 🎯 Whether you work in engineering, product, research, or venture, this is your chance to learn how these leaders bring AI innovation to life — and scale it beyond the lab. 🎟️ Register here to save your spot: https://luma.com/eyx559im

📣 Founders and startup leaders! 👋 BenchSci is excited to present an exclusive, in-person event: How to Close Your Funding Round in 3 Weeks. Join Liran Belenzon, BenchSci's Co-founder & CEO, for a practical and insightful session on the art of startup fundraising. Liran has successfully led BenchSci through multiple funding rounds—from seed to Series D, raising over $200M from top global investors. 💰 In this talk, he'll share the proven framework he’s used to help founders accelerate their fundraising process—often closing rounds in just a few weeks. Whether you’re preparing for your first raise or planning your next round, this session will give you the clarity, confidence, and actionable strategies to get it done right—and fast. Space is limited, reserve your spot here: https://lnkd.in/gUDWQJpz

🎉 As BenchSci marks 10 years, we're celebrating by paying it forward to the Toronto startup community! This December, we're launching events to share what we've learned and support the next generation of founders. 🗓️ First up: December 2 at the BenchSci office 💡 Liran Belenzon will share his framework: “How to Close Your Fundraising in 3 Weeks.” If you’re raising, scaling, or just starting out, this one’s for you 📈 👉 Save your spot: https://lnkd.in/gUDWQJpz

We’re proud to announce a three-year license agreement with Sanofi to deploy BenchSci’s ASCEND™ platform across its global preclinical research organization.  🎉 Through ASCEND—our neuro-symbolic disease biology AI platform—Sanofi scientists will gain a powerful co-pilot designed to unravel the black box of disease biology. By integrating public scientific evidence with internal data into ASCEND’s Biological Evidence Knowledge Graph (BEKG), researchers can connect insights across disciplines, accelerate hypothesis generation, and optimize experimental design. We’re thrilled to support Sanofi in building a long-term, AI-enabled foundation for innovation in drug discovery. Read more about our partnership here: https://lnkd.in/gTBnvs5d

Exciting news from BenchSci: We’re partnering with Thermo Fisher Scientific to deliver new AI-powered research tools that accelerate experimental design and boost R&D productivity. 🚀   By combining BenchSci’s ASCEND™ AI technology with Thermo Fisher’s global footprint in lab equipment and services, we’ll empower scientists to: 🔬Decode complex biomedical evidence faster 📄 Navigate and interpret research literature with precision 🧪Optimize reagent selection and lab resources Together, we’re creating digital capabilities that help researchers move from scientific ideas to life-saving medicines more efficiently and cost-effectively. We’re thrilled to work with Thermo Fisher on this mission to transform preclinical research and drug discovery. Read the full announcement: https://lnkd.in/gftgv5My  

Big news! BenchSci has once again made The Globe and Mail’s Report on Business Top Growing Companies List! 🎉 🎉 This recognition belongs to our people. Every BenchScier brings expertise, dedication, and passion to tackle one of pharma’s hardest problems—unraveling disease biology. We’re proud of what we’ve accomplished together and even more excited about what’s ahead. A massive thank you to our team for driving our mission forward and to our customers and partners for being a part of our journey. Check out the full list here: https://lnkd.in/g2C_MKpG

🔬 Disease biology remains a black box. Not because we lack data, but because the evidence we need is scattered across millions of resources, including disconnected databases, publications, study documents, and more. This fragmentation fuels failed research projects and clinical trials, costing billions and delaying life-saving therapies. ✨ At BenchSci, we’ve achieved what others thought was impossible. We’ve built LENS —the first system able to extract complete, evidence-based insights from any biomedical paper with >90% completeness and <1% hallucination. LENS powers our Biological Evidence Knowledge Graph (BEKG), a living, evidence-backed map of disease biology. Together, they create the foundation for neuro-symbolic AI, empowering scientists and organizations to deeply understand the underlying disease biology, connect hidden insights, and unlock discovery at scale. 💡 The future of drug discovery isn’t just more AI. It’s evidence-based AI. 👉 Learn how we’re unlocking the black box: https://lnkd.in/di5VkiDc 

Biomedical researchers are drowning in a sea of scientific information. The sheer volume of data creates bottlenecks and inefficiencies, and even powerful LLMs can struggle with the lack of traceable, structured knowledge. This new case study from BioPharmaTrend.com shows how our ASCEND platform addresses this core challenge. It explains how we use a neurosymbolic AI approach to build a robust, evidence-based knowledge graph that decodes, harmonizes, and structures biomedical data. This ensures every insight is grounded in real-world evidence to transform R&D and accelerate drug discovery. Read the full case study to see how we're building a new foundation for biomedical reasoning: https://lnkd.in/geQ6BsM9

Huge news from BenchSci! 🎉 We're thrilled to announce that Dr. Mikael Dolsten, former Chief Scientific Officer and President of Pfizer R&D, has joined our Board of Directors. Dr. Dolsten brings over three decades of unparalleled leadership and scientific expertise, having overseen the approval of 36+ medicines and vaccines and progressing 150+ drug candidates to clinical studies. His vast experience will be instrumental as we push the boundaries of AI in preclinical research. We are honoured that Dr. Dolsten has chosen to join us and lend his immense talent to our mission. As our CEO, Liran Belenzon (he/him), shared, “His incredible depth of experience in R&D innovation, his understanding of the challenges pharmaceutical companies face, and his unique perspective will be game-changing for us. Dr. Dolsten’s leadership will help us push the limits of what’s possible in drug discovery and, most importantly, bring life-saving treatments to patients faster.” With Dr. Dolsten's guidance, we're even more empowered to accelerate preclinical drug discovery and solve the number one reason projects fail: getting the biology wrong. Learn more in our official press release: https://lnkd.in/gUZvPkcm

Today, we’re proud to announce two significant additions to our leadership team! 💡 John Jackson joins us as Chief Technology Officer (CTO). With more than 20 years of experience as a CTO and CEO, John is an accomplished leader in healthcare data, AI, and technical innovation. His expertise in building advanced, scalable technology solutions will drive the continued development of our ASCEND platform, empowering scientists to accelerate drug discovery worldwide. 📈 Peter Grandsard joins as Fractional Senior Vice President of Strategy. With nearly three decades at Amgen, Peter is a recognized leader in research and development, well recognized for advancing the use of automation and data science in preclinical R&D. Having championed our ASCEND platform, he is eager to shape innovation that is closely aligned with the needs of scientists and the healthcare community. These appointments mark an exciting step forward in BenchSci’s mission to empower scientists and accelerate breakthroughs in drug discovery. Check out our full announcement for more: https://lnkd.in/gpWW93Za